Home
Scholarly Works
Excitatory and Inhibitory Actions of Isoprostanes...
Journal article

Excitatory and Inhibitory Actions of Isoprostanes in Human and Canine Airway Smooth Muscle 1 1 This study was supported by an operating grant and a Scientist Award from the Medical Research Council of Canada (to L.J.J.).

Abstract

Isoprostanes are generated nonenzymatically during free radical-mediated lipid peroxidation, and are used clinically and experimentally as markers of oxidative stress. However, their biological effects are poorly understood. We examined the effects of seven different 8-isoprostanes in human and canine airway smooth muscles. In large order airways (carina) of the human, several isoprostanes evoked powerful contractions, with 8-iso-prostaglandin (PG) E(2), 8-iso-PGF(1 alpha), and 8-iso-PGF(2 alpha) being the most efficacious (and with logEC(50) values of 7.0, 5.9, and 6.2 microM, respectively). These contractions were sensitive to the prostanoid TP receptor antagonist ICI 192,605 (0.1-1 microM), but not the EP prostanoid receptor antagonist AH-6809 (50 microM), or the leukotriene receptor antagonists monteleukast or ICI 198,615 (both 1 microM). Qualitatively similar results were obtained in small order human airways (<2 mm o.d.), except that the isoprostanes were generally slightly less potent. None of the isoprostanes had any marked excitatory effect in canine airways. In carbachol-preconstricted tissues (pretreated with ICI 192,605 to block any potential contraction), several isoprostanes completely relaxed canine airways: 8-iso-PGE(1), 8-iso-PGE(2), and 8-iso-PGF(3 alpha) were the most potent, with logIC(50) values of 6.9, 6.9, and 5.7, respectively. Only 8-iso-PGF(3 alpha) relaxed human airways (logIC(50) = 4.9). Our results show that several 8-isoprostanes are highly biologically active in human and canine airways, evoking both excitatory and/or inhibitory effects, and that these effects are compound, species, and tissue dependent.

Authors

Janssen LJ; Premji M; Netherton S; Catalli A; Cox G; Keshavjee S; Crankshaw DJ

Journal

Journal of Pharmacology and Experimental Therapeutics, Vol. 295, No. 2, pp. 506–511

Publisher

Elsevier

Publication Date

January 1, 2000

DOI

10.1016/s0022-3565(24)38932-3

ISSN

0022-3565

Contact the Experts team